← Patent-cliff monitor Loss of exclusivity May 2043 latest FDA-listed patent expiry
Drug detail Brand name OGSIVEO Active ingredient NIROGACESTAT HYDROBROMIDE Strength EQ 50MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2023 Marketing status DISCN
Listed patents Patent Expires Type 11925619 May 2043 use U-3754 11938116 May 2043 use U-3754 12036207 May 2043 use U-3754 11951096 May 2043 use U-3754 11957662 May 2043 use U-3754 11872211 May 2043 use U-3754 12138246 May 2043 use U-3754 12011435 May 2043 use U-3754 12011434 May 2043 use U-3754 11925620 May 2043 use U-3754 11807611 September 2042 product 11844780 September 2042 product 11504354 July 2042 product 11612588 July 2042 product 12247012 July 2042 product 12110277 July 2042 product 12234210 July 2042 product 12599587 July 2042 product 11884635 August 2039 product 12297177 August 2039 product 12116347 August 2039 product 11884634 August 2039 product 11905255 August 2039 product 11845732 August 2039 substance 10710966 August 2039 substance 10941118 August 2039 substance 11820748 August 2039 product 10590087 August 2039 substance 7795447 August 2030 substance
Regulatory exclusivity Code Expires ODE-452 November 2030 NCE November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.